Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 4/20 | 0.41 |
| ▸ | PLK1 | P53350 | 1/20 | 0.35 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15415471 | 0.95 | KDM4C (0.38) | KDM4C | |
| SCHEMBL15415827 | 0.91 | TBXA2R (0.35) | KDM4CTBXA2R | |
| SCHEMBL15416045 | 0.91 | BCL6 (0.38) | TBXA2R | |
| SCHEMBL15416116 | 0.89 | KDM4C (0.39) | KDM4CTBXA2R | |
| SCHEMBL15416230 | 0.89 | KMT2A (0.34) | KDM4CTBXA2R | |
| SCHEMBL15428321 | 0.89 | KMT2A (0.45) | KDM4CTBXA2R | |
| SCHEMBL15416302 | 0.88 | MEN1 (0.42) | KDM4C | |
| SCHEMBL15415377 | 0.88 | TBXA2R (0.34) | KDM4CTBXA2R | |
| SCHEMBL15416279 | 0.87 | KDM4C (0.34) | KDM4C | |
| SCHEMBL15416207 | 0.87 | TBXA2R (0.36) | TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2872502-B1 | NOVEL INDAZOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2016-08-24 | — | — | EP | claimed |
| US-20160200741-A1 | Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection | HOFFMANN-LA ROCHE INC. (US) | 2016-07-14 | — | — | US | claimed |
| US-9206191-B2 | Indazoles for the treatment and prophylaxis of respiratory syncytial virus infection | HOFFMANN-LA ROCHE INC. (US) | 2015-12-08 | — | — | US | claimed |
| US-20150158879-A1 | Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection | HOFFMANN-LA ROCHE INC. (US) | 2015-06-11 | — | — | US | claimed |
| EP-3177299-A1 | COMBINATION THERAPY FOR TREATING A PARAMYXOVIRUS | Alios Biopharma, Inc. (US) | 2017-06-14 | — | — | EP | disclosed |
| EP-2872502-B1 | NOVEL INDAZOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2016-08-24 | — | — | EP | disclosed |
| EP-2872502-B1 | NOVEL INDAZOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2016-08-24 | — | — | EP | disclosed |
| US-20160200741-A1 | Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection | HOFFMANN-LA ROCHE INC. (US) | 2016-07-14 | — | — | US | disclosed |
| US-20160200741-A1 | Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection | HOFFMANN-LA ROCHE INC. (US) | 2016-07-14 | — | — | US | disclosed |
| US-20160200741-A1 | Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection | HOFFMANN-LA ROCHE INC. (US) | 2016-07-14 | — | — | US | disclosed |
| US-20160045528-A1 | COMBINATION THERAPY FOR TREATING A PARAMYXOVIRUS | ALIOS BIOPHARMA, INC. | 2016-02-18 | — | — | US | disclosed |
| WO-2016022464-A1 | COMBINATION THERAPY FOR TREATING A PARAMYXOVIRUS | ALIOS BIOPHARMA, INC. (US) | 2016-02-11 | — | — | WO | disclosed |
| US-9206191-B2 | Indazoles for the treatment and prophylaxis of respiratory syncytial virus infection | HOFFMANN-LA ROCHE INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-9206191-B2 | Indazoles for the treatment and prophylaxis of respiratory syncytial virus infection | HOFFMANN-LA ROCHE INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-20150158879-A1 | Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection | HOFFMANN-LA ROCHE INC. (US) | 2015-06-11 | — | — | US | disclosed |
| US-20150158879-A1 | Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection | HOFFMANN-LA ROCHE INC. (US) | 2015-06-11 | — | — | US | disclosed |
| US-20150158879-A1 | Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection | HOFFMANN-LA ROCHE INC. (US) | 2015-06-11 | — | — | US | disclosed |
| EP-2872502-A1 | NOVEL INDAZOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2015-05-20 | — | — | EP | disclosed |
| WO-2014009302-A1 | NOVEL INDAZOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2014-01-16 | — | — | WO | disclosed |
| WO-2014009302-A1 | NOVEL INDAZOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2014-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160045528-A1 | COMBINATION THERAPY FOR TREATING A PARAMYXOVIRUS | MAVS, EIF2AK2, SARS1 | KDM4C 4022/4885PLK1 825/4885TBXA2R 1443/4885 |
| US-20150158879-A1 | Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection | ADORA3, ADORA1, BRS3 | KDM4C 3231/4885PLK1 3496/4885TBXA2R 340/4885 |
| US-20160200741-A1 | Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection | ADORA3, ADORA1, BRS3 | KDM4C 3231/4885PLK1 3496/4885TBXA2R 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.